SAMUEL AMPONSAH: Open Payments
NPI 1285394262 · ABERDEEN, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$787 in 51 payments from 10 companies in 2025. Trend: 2023 $165 · 2024 $332 · 2025 $787
Food & beverage: $787
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 18 | $207 |
| E.R. Squibb & Sons, L.L.C. | 7 | $127 |
| Janssen Pharmaceuticals, Inc | 5 | $102 |
| Teva Pharmaceuticals USA, Inc. | 5 | $78 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $72 |
| Otsuka America Pharmaceutical, Inc. | 4 | $65 |
| Neurocrine BioSciences, Inc. | 3 | $61 |
| Lundbeck LLC | 2 | $29 |
| Alkermes, Inc. | 2 | $29 |
| Vanda Pharmaceuticals Inc. | 1 | $16 |
Products named: VRAYLAR, COBENFY, REXULTI, CAPLYTA, SPRAVATO, INGREZZA, UZEDY, INVEGA SUSTENNA.
Industry payments across NJ — which companies pay providers there.
